Post Exposure Prophylaxis News and Research

RSS

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Ethiopia's workplace HIV/AIDS policy aims to help employers, employees nationwide

Ethiopia's new HIV/AIDS workplace policy, instituted in January by the government in cooperation with the country's main employees' and employers' associations, "is expected to protect job seekers from mandatory HIV tests, while facilitating voluntary counseling and testing and defending the right of employees living with HIV to medical leave or job re-allocation," PlusNews reports.

29 Mar 2012

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.

9 Sep 2011

HRSA announces $5.1M in awards as part of Ryan White HIV/AIDS Program

The Health Resources and Services Administration (HRSA) today announced awards of $5.1 million to provide training and technical assistance (TA) as part of the Ryan White HIV/AIDS Program, which provides HIV-related services in the United States for those who do not have sufficient health care coverage or financial resources for coping with HIV disease.

8 Sep 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

New international guidelines launched to protect health workers against HIV, TB

Health workers are at the frontline in providing prevention, treatment and care for people living with HIV and TB throughout the world. They are at risk of occupational exposure to HIV and TB but often themselves lack adequate access to protection and treatment. To address this gap, new international guidelines are being launched today by the International Labour Organization, WHO and the Joint United Nations Programme on HIV/AIDS.

20 Nov 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

BD, PEPFAR commence multi-year initiative to improve blood collection practices in African clinics, hospitals

BD (Becton, Dickinson and Company), a leading global medical technology company, and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Department of Health and Human Services' Centers for Disease Control and Prevention (CDC) today set in motion a joint, multi-year initiative to improve blood collection practices in African clinics and hospitals.

From BD (Becton, Dickinson and Company) 22 Jun 2010

Use of lubricants with anal sex associated with increased risk of rectal sexually transmitted infections

The risk of acquiring HIV through unprotected anal sex is at least 20 times greater than with unprotected vaginal sex and increases if other infections are already present in the rectal lining. Could the use of lubricants - at least certain kinds - be another risk factor among men and women who engage in receptive anal intercourse? Two studies presented today at the International Microbicides Conference in Pittsburgh, suggest the answer is yes.

27 May 2010

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

Single inoculation for rabies vaccination

...

21 Sep 2009

St. Vincent develops the first-ever HIV educational widget

Saint Vincent Catholic Medical Centers and the New York State Department of Health (DOH) today unveiled a novel Web-based technology to rapidly instruct health care providers throughout New York State about HIV diagnosis and prevention.

10 Sep 2009

NIAID funds Nanotherapeutic for developing an inhaled version of the injectable antiviral drug

Nanotherapeutics, Inc., today announced that it has been awarded a $30.9 Million, 5-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop an inhaled version of the injectable antiviral drug, cidofovir, for non-invasive, post-exposure prophylaxis and treatment of the Category A bioterrorism agent smallpox (Variola major).

25 Aug 2009

Vietnamese HIV/AIDS Department announces funding for prevention efforts

Vietnamese officials announced recently that about 678 billion dong, or about $38.7 million, will be allocated for HIV/AIDS prevention efforts in the country in 2009, the VNA/VietnamPlus.com reports.

14 May 2009

Lethal risks associated with preparing dog meat

Eating dog meat is common in many Asian countries, but research conducted as part of the South East Asian Infectious Diseases Clinical Research Network has discovered a potentially lethal risk associated with preparing dog meat: rabies.

16 Mar 2009

Three bitten by rabid dog in Britain

A dog imported into Britain from Sri Lanka has died of rabies but not before it had bitten three people.

28 Apr 2008

Sanofi Pasteur enters agreement eith Crucell for next-generation biologicals against rabies

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

4 Jan 2008